Journal
JOURNAL OF VIROLOGY
Volume 83, Issue 13, Pages 6416-6428Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00445-09
Keywords
-
Categories
Funding
- Cancer Research UK
- St. Bartholomew's and The Royal London Charitable Foundation
- The Health Foundation
- MRC [G0601891] Funding Source: UKRI
- Medical Research Council [G0601891] Funding Source: researchfish
Ask authors/readers for more resources
A key impediment to successful cancer therapy with adenoviral vectors is the inefficient transduction of malignant tissue in vivo. Compounding this problem is the lack of cancer-specific targets, coupled with a shortage of corresponding high-efficiency ligands, permitting selective retargeting. The epithelial cell-specific integrin alpha v beta 6 represents an attractive target for directed therapy since it is generally not expressed on normal epithelium but is upregulated in numerous carcinomas, where it plays a role in tumor progression. We previously have characterized a high-affinity, alpha v beta 6-selective peptide (A20FMDV2) derived from VP1 of foot-and-mouth disease virus. We generated recombinant adenovirus type 5 (Ad5) fiber knob, incorporating A20FMDV2 in the HI loop, for which we validated the selectivity of binding and functional inhibition of alpha v beta 6. The corresponding alpha v beta 6-retargeted virus Ad5-EGFP(A20) exhibited up to 50-fold increases in coxsackievirus-and-adenovirus-receptor-independent transduction and up to 480-fold-increased cytotoxicity on a panel of alpha v beta 6-positive human carcinoma lines compared with Ad5-EGFPWT. Using an alpha v beta 6-positive (DX3-beta 6) xenograft model, we observed a similar to 2-fold enhancement in tumor uptake over Ad5-EGFPWT following systemic delivery. Furthermore, similar to 5-fold-fewer Ad5-EGFP(A20) genomes were detected in the liver (P = 0.0002),correlating with reduced serum transaminase levels and E1A expression. Warfarin pretreatment, to deplete coagulation factors, did not improve tumor uptake significantly with either virus but did significantly reduce liver sequestration and hepatic toxicity. The ability of Ad5-EGFP(A20) to improve delivery to alpha v beta 6, combined with its reduced hepatic tropism and toxicity, highlights its potential as a prototype virus for future clinical investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available